Formulation of benznidazole-lipid nanocapsules: Drug release, permeability, biocompatibility, and stability studies

Arrúa, Eva Carolina; Hartwig, Olga; Loretz, Brigitta; Murgia, Xabier; Ho, Duy‐Khiet; Bastiat, Guillaume; Lehr, Claus‐Michael; Salomón, Claudio J.

doi:10.1016/j.ijpharm.2023.123120

Cited by 7 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During gastrointestinal transit, biodegradable nano-particles are degraded or not absorbed, leaving only released BNZ available for absorption [39,40]. Other studies determined the release profile of BNZ in different media [41][42][43][44] and its permeability across Caco-2 cells [43,44].…”

Section: Oral Bnz-based Nanomedicines Aimed To Increase Bnz Solubilitymentioning

confidence: 99%

Nanomedicines against Chagas disease: a critical review

Morilla,

Ghosal,

Romero

2024

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

Chagas disease (CD) is the most important endemic parasitosis in South America and represents a great socioeconomic burden for the chronically ill and their families. The only currently available treatment against CD is based on the oral administration of benznidazole, an agent, developed in 1971, of controversial effectiveness on chronically ill patients and toxic to adults. So far, conventional pharmacological approaches have failed to offer more effective and less toxic alternatives to benznidazole. Nanomedicines reduce toxicity and increase the effectiveness of current oncological therapies. Could nanomedicines improve the treatment of the neglected CD? This question will be addressed in this review, first by critically discussing selected reports on the performance of benznidazole and other molecules formulated as nanomedicines in in vitro and in vivo CD models. Taking into consideration the developmental barriers for nanomedicines and the degree of current technical preclinical efforts, a prospect of developing nanomedicines against CD will be provided. Not surprisingly, we conclude that structurally simpler formulations with minimal production cost, such as oral nanocrystals and/or parenteral nano-immunostimulants, have the highest chances of making it to the market to treat CD. Nonetheless, substantive political and economic decisions, key to facing technological challenges, are still required regarding a realistic use of nanomedicines effective against CD.

show abstract

Section: Oral Bnz-based Nanomedicines Aimed To Increase Bnz Solubilitymentioning

confidence: 99%

Nanomedicines against Chagas disease: a critical review

Morilla,

Ghosal,

Romero

2024

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

show abstract

“…Despite these advances, the great challenge and concern regarding the applicability of nanotechnology is to solve treatment problems such as drug targeting, drug resistance mechanisms, and the effects of prolonged release compared to traditional drugs. Most of the work with nanosystems has not explored these points, and the currently restricted clinical trials research should focus on new alternative treatments in detriment to the traditional ones, seeking for more efficient and less toxic drugs [170][171][172].…”

Section: Chagas Disease Is Still a Current Health Problemmentioning

confidence: 99%

The End Justifies the Means: Chagas Disease from a Perspective of the Host–Trypanosoma cruzi Interaction

Rossi,

de Souza,

Ramirez

2024

Life

View full text Add to dashboard Cite

The neglected Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi. Despite CD dispersion throughout the world, it prevails in tropical areas affecting mainly poor communities, causing devastating health, social and economic consequences. Clinically, CD is marked by a mildly symptomatic acute phase, and a chronic phase characterized by cardiac and/or digestive complications. Current treatment for CD relies on medications with strong side effects and reduced effectiveness. The complex interaction between the parasite and the host outlines the etiology and progression of CD. The unique characteristics and high adaptability of T. cruzi, its mechanisms of persistence, and evasion of the immune system seem to influence the course of the disease. Despite the efforts to uncover the pathology of CD, there are many gaps in understanding how it is established and reaches chronicity. Also, the lack of effective treatments and protective vaccines constitute challenges for public health. Here, we explain the background in which CD is established, from the peculiarities of T. cruzi molecular biology to the development of the host’s immune response leading to the pathophysiology of CD. We also discuss the state of the art of treatments for CD and current challenges in basic and applied science.

show abstract

“…These alternatives include the development of new formulations capable of increasing drug bioavailability and improving biopharmaceutical properties in the search for new molecules with potential trypanocidal activity. In addition, the search for these alternatives may contribute to the reduction of side effects associated with the current treatment and potentially increase therapeutic success for patients affected by the disease also in the chronic phase [ 55 , 56 , 57 ].…”

Section: Chagas Diseasementioning

confidence: 99%

From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease

Gomes,

Medeiros,

Alves Pereira

et al. 2023

IJMS

View full text Add to dashboard Cite

Chagas disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi. Benznidazole and nifurtimox are the two approved drugs for their treatment, but both drugs present side effects and efficacy problems, especially in the chronic phase of this disease. Therefore, new molecules have been tested with promising results aiming for strategic targeting action against T. cruzi. Several studies involve in vitro screening, but a considerable number of in vivo studies describe drug bioavailability increment, drug stability, toxicity assessment, and mainly the efficacy of new drugs and formulations. In this context, new drug delivery systems, such as nanotechnology systems, have been developed for these purposes. Some nanocarriers are able to interact with the immune system of the vertebrate host, modulating the immune response to the elimination of pathogenic microorganisms. In this overview of nanotechnology-based delivery strategies for established and new antichagasic agents, different strategies, and limitations of a wide class of nanocarriers are explored, as new perspectives in the treatment and monitoring of Chagas disease.

show abstract

Formulation of benznidazole-lipid nanocapsules: Drug release, permeability, biocompatibility, and stability studies

Cited by 7 publications

References 55 publications

Nanomedicines against Chagas disease: a critical review

Nanomedicines against Chagas disease: a critical review

The End Justifies the Means: Chagas Disease from a Perspective of the Host–Trypanosoma cruzi Interaction

From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease

Contact Info

Product

Resources

About